Archer-Daniels-Midland announced on May 22, 2025, new findings from a clinical study investigating the effects of Bifidobacterium animalis subsp. lactis CECT 8145 (PRIOME® Metabolic Health or PRIOME® MH) in adult dogs. The study evaluated both probiotic and heat-treated postbiotic forms of the strain.
The randomized, double-blind, placebo-controlled clinical study, involving 45 healthy adult dogs, showed a significant reduction in postprandial blood glucose levels in dogs receiving the postbiotic, compared to a placebo group, during the weight loss phase. This suggests a potential role for the postbiotic form in supporting metabolic health.
Sophie Nixon, Head of R&D Clinical Research for Pet & Animal Wellbeing at ADM, highlighted these results as an important step in understanding the potential for postbiotics in pet metabolic health, an area historically underserved by biotic ingredients. These findings contribute to ADM's expanding body of evidence for postbiotics in pet health research.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.